Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop Benjamin EJ; Chen PS; Bild DE; Mascette AM; Albert CM; Alonso A; Calkins H; Connolly SJ; Curtis AB; Darbar D; Ellinor PT; Go AS; Goldschlager NF; Heckbert SR; Jalife J; Kerr CR; Levy D; Lloyd-Jones DM; Massie BM; Nattel S; Olgin JE; Packer DL; Po SS; Tsang TS; Van Wagoner DR; Waldo AL; Wyse DGCirculation 2009[Feb]; 119 (4): 606-18The National Heart, Lung, and Blood Institute convened an expert panel April 28 to 29, 2008, to identify gaps and recommend research strategies to prevent atrial fibrillation (AF). The panel reviewed the existing basic scientific, epidemiological, and clinical literature about AF and identified opportunities to advance AF prevention research. After discussion, the panel proposed the following recommendations: (1) enhance understanding of the epidemiology of AF in the population by systematically and longitudinally investigating symptomatic and asymptomatic AF in cohort studies; (2) improve detection of AF by evaluating the ability of existing and emerging methods and technologies to detect AF; (3) improve noninvasive modalities for identifying key components of cardiovascular remodeling that promote AF, including genetic, fibrotic, autonomic, structural, and electrical remodeling markers; (4) develop additional animal models reflective of the pathophysiology of human AF; (5) conduct secondary analyses of already-completed clinical trials to enhance knowledge of potentially effective methods to prevent AF and routinely include AF as an outcome in ongoing and future cardiovascular studies; and (6) conduct clinical studies focused on secondary prevention of AF recurrence, which would inform future primary prevention investigations.|*National Heart, Lung, and Blood Institute (U.S.)[MESH]|Animals[MESH]|Atrial Fibrillation/*epidemiology/*prevention & control[MESH]|Humans[MESH]|Risk Factors[MESH]|United States[MESH] |